High-flow Nasal Oxygenation in Obese Patients During Colonoscopy: a Randomized Controlled Trial (COCOON) (COCOON)
High-flow Nasal Oxygenation in Obese Patient During Colonoscopy: a Randomized Controlled Trial: the COCOON Trial
The goal of this clinical trial is to determine whether high-flow oxygen therapy (HFOT) is more effective than conventional oxygen therapy (COT) in reducing episodes of intraoperative oxygen desaturation (oxygen saturation [SpO2] ≤ 90%) during colonoscopy under general anesthesia in adults with a body mass index (BMI) of 30 kg/m² or higher.
The main question it aims to answer is:
Does high-flow oxygen therapy reduce the occurrence of intraoperative oxygen desaturation compared with conventional oxygen therapy during colonoscopy under general anesthesia? Researchers will compare high-flow oxygen therapy with conventional oxygen therapy to determine whether high-flow oxygen therapy reduces the occurrence of intraoperative oxygen desaturation.
Participants will:
Be screened during their anesthesia consultation between 60 days and 48 hours before the scheduled colonoscopy.
Be randomly assigned (1:1) to receive either conventional oxygen therapy or high-flow oxygen therapy. Receive standard monitoring and 3 minutes of pre-oxygenation according to their assigned treatment group.
Undergo colonoscopy under general anesthesia while breathing spontaneously. Be monitored for oxygen desaturation during the procedure. Have ventilatory and hemodynamic data recorded during the procedure and collected immediately after the colonoscopy.
The study will include adults scheduled for a colonoscopy at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Prospective, multicentre, controlled, randomized, parallel-group superiority trial with a 1:1 allocation ratio, with participants blinded to the oxygen treatment received, comparing high-flow oxygen therapy (HFOT) with conventional oxygen therapy (COT) delivered through an oxygen mask. The study aims to determine whether HFOT is more effective than COT in preventing intraoperative oxygen desaturation during colonoscopy under general anesthesia in participants with a body mass index (BMI) of 30 kg/m² or higher.
Adults with a body mass index (BMI) of 30 kg/m² or higher who are scheduled to undergo a colonoscopy at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.
After written informed consent has been obtained, participants will be randomized by the study investigators to one of the two treatment groups: conventional oxygen therapy (COT); high-flow oxygen therapy (HFOT).
A computer-generated randomization list with a 1:1 allocation ratio and variable block sizes will be prepared by a statistician from the URC Paris Nord Secteur Ouest, in accordance with the sponsor's procedures. Allocation will be concealed, as the randomization list will not be accessible to the study team. The list will be directly integrated into CleanWEB™, a secure, centralized, 24- hour Internet platform, which will also be used for the electronic case report form (eCRF).
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Jules STERN
- 電話番号:+33140258080
- メール:jules.stern@aphp.fr
研究連絡先のバックアップ
- 名前:Ines CHIBANE, +33140257961
- メール:ines.chibane@aphp.fr
研究場所
-
-
-
Clichy、フランス、92110
- Hôpital Beaujon, département d'anesthésie-réanimation, 100 boulevard du Général Leclerc
-
コンタクト:
- Stéphanie SIGAUT, Principal Investigator
-
Colombes、フランス、92700
- Hôpital Louis Mourier, département d'anesthésie-réanimation, 178 rue des Renouillers
-
Paris、フランス、75018
- Hôpital Bichat-Claude Bernard, département d'anesthésie-réanimation, 46 rue Henri Huchard
-
コンタクト:
- Jules STERN, Principal Investigator
- 電話番号:+33140258080
- メール:jules.stern@aphp.fr
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 18 years or older.
- Body mass index (BMI) of 30 kg/m² or higher.
- Scheduled to undergo a colonoscopy under general anesthesia with spontaneous breathing at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.
- Affiliated with a social security scheme.
- Free, informed and written consent signed.
Exclusion Criteria:
-
Colonoscopy in a participant at high risk of aspiration requiring orotracheal intubation, defined by at least one of the following:
- Symptomatic or severe gastroesophageal reflux disease, notably with frequent regurgitation (≥ 2 episodes per week), mainly occurring in the supine position;
- Hiatal hernia;
- History of bariatric surgery (sleeve gastrectomy, gastric bypass);
- Neurodegenerative disease requiring airway protection during colonoscopy.
-
Emergency colonoscopy.
-
Chronic respiratory failure.
-
Severe heart failure.
-
Allergy to propofol.
-
Pregnant or breastfeeding woman.
-
Adult under legal protection (guardianship or curatorship).
-
Beneficiary of State Medical Aid (Aide Médicale de l'État, AME).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
アクティブコンパレータ:Conventional oxygen therapy
Participants assigned to the conventional oxygen therapy group will receive 100% oxygen at 6 L/min through an oxygen capnography mask during the 3-minute pre-oxygenation period and throughout the procedure. After pre-oxygenation, propofol will be administered by target-controlled intravenous infusion, with an initial target concentration of 2 µg/mL. The anesthetist may adjust the target concentration to achieve deep sedation according to American Society of Anesthesiologists (ASA) criteria. The colonoscopy will be performed while participants breathe spontaneously. |
100% oxygen delivered at a flow rate of 6 L/min through an oxygen capnography mask, during the 3-minute pre-oxygenation period and throughout the colonoscopy performed under general anesthesia (propofol target-controlled infusion) with spontaneous breathing.
他の名前:
|
|
実験的:High-flow oxygen therapy
Participants assigned to the high-flow oxygen therapy group will receive 100% oxygen at 50 L/min through an Optiflow® system (Fisher & Paykel Healthcare) during the 3-minute pre-oxygenation period and throughout the procedure. After pre-oxygenation, propofol will be administered by target-controlled intravenous infusion, with an initial target concentration of 2 µg/mL. The anesthetist may adjust the target concentration to achieve deep sedation according to American Society of Anesthesiologists (ASA) criteria. The colonoscopy will be performed while participants breathe spontaneously. |
100% oxygen delivered at a flow rate of 50 L/min through an Optiflow® high-flow nasal system (Fisher & Paykel Healthcare), during the 3-minute pre-oxygenation period and throughout the colonoscopy performed under general anesthesia (propofol target-controlled infusion) with spontaneous breathing.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of participants with at least one episode of oxygen desaturation (SpO2 ≤ 90%) during the procedure
時間枠:From the start to the end of the procedure (Day 0)
|
Oxygen desaturation is defined as a peripheral oxygen saturation (SpO2) ≤ 90%, regardless of its duration, measured by continuous pulse oximetry during the colonoscopy performed under general anesthesia. |
From the start to the end of the procedure (Day 0)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Total number of episodes of oxygen desaturation (SpO₂ ≤ 90%) during the procedure
時間枠:From the start to the end of the procedure (Day 0)
|
Number of desaturation episodes (SpO2 ≤ 90%) per participant, determined from continuously recorded pulse oximetry data. |
From the start to the end of the procedure (Day 0)
|
|
Cumulative duration of oxygen desaturation episodes (SpO2 ≤ 90%) relative to the total duration of the procedure
時間枠:From the start to the end of the procedure (Day 0)
|
Total time (in seconds) spent with SpO2 ≤ 90%, divided by the total duration of the procedure, i.e. the fraction of procedure time spent in desaturation (between 0 and 1), determined from continuously recorded pulse oximetry data. |
From the start to the end of the procedure (Day 0)
|
|
Occurrence of an episode of hypotension, defined as systolic blood pressure (SBP) < 100 mmHg, during the procedure
時間枠:From the start to the end of the procedure (Day 0)
|
Determined from continuously recorded non-invasive blood pressure data. |
From the start to the end of the procedure (Day 0)
|
|
Occurrence of an episode of severe bradycardia, defined as heart rate < 40 beats/minute, during the procedure
時間枠:From the start to the end of the procedure (Day 0)
|
Determined from continuously recorded heart rate data. |
From the start to the end of the procedure (Day 0)
|
|
Use of orotracheal intubation during the procedure
時間枠:From the start to the end of the procedure (Day 0)
|
Collected from the medical record and reported in the eCRF. |
From the start to the end of the procedure (Day 0)
|
|
Occurrence of a cardiac arrest during the procedure
時間枠:From the start to the end of the procedure (Day 0)
|
Cardiorespiratory arrest, collected from the medical record and reported in the eCRF |
From the start to the end of the procedure (Day 0)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- APHP251722
- 2026-A00471-50 (その他の識別子:IDRCB)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。